Cambridge, Mass.-based biotechnology company Seres Therapeutics Inc. appointed Meryl Zausner as a board member.
Zausner previously served as chief financial and administrative officer of Novartis AG unit Novartis Pharmaceuticals Corp. and a member of the U.S. pharmaceutical executive committee and global finance leadership team.
Seres Therapeutics develops medicines using live bacteria to treat diseases resulting from functional deficiencies of microorganisms within the body.